Baird lowered the firm’s price target on Inspire Medical to $200 from $220 and keeps an Outperform rating on the shares. The firm said the company remains a best-in-class idea after the company delivered +30% revenue growth and remains on track to deliver upside to raised revenue/profit outlook.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Enhances Investor Relations and Share Value
- Inspire Medical Systems, Inc. Announces Second Quarter 2024 Financial Results and Updates 2024 Outlook
- Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
- INSP Earnings this Week: How Will it Perform?
- Inspire Medical Systems, Inc. Announces FDA Approval of the Inspire V System